Roche Holding AG

SWX:ROG 주식 리포트

시가총액: CHF 257.5b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Roche Holding 향후 성장

Future 기준 점검 2/6

Roche Holding (는) 각각 연간 9.3% 및 3.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 10.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 34.8% 로 예상됩니다.

핵심 정보

9.3%

이익 성장률

10.28%

EPS 성장률

Pharmaceuticals 이익 성장10.5%
매출 성장률3.1%
향후 자기자본이익률34.76%
애널리스트 커버리지

Good

마지막 업데이트12 Mar 2026

최근 향후 성장 업데이트

분석 기사 • Feb 03

Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year

As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...

Recent updates

내러티브 업데이트 • Mar 21

ROG: 2026 Clinical Catalysts And Obesity Data Will Drive Upside Potential

Analysts now place fair value for Roche Holding at CHF 363.47. This is a modest adjustment supported by mixed recent research that highlights softer revenue growth and profit margin assumptions, a higher future P/E, and a wider spread of Street price targets ranging from CHF 325 to CHF 390, alongside ratings that span from Neutral to Buy.
내러티브 업데이트 • Mar 07

ROG: Genomics Pricing And Cautious Pipeline Outlook Will Constrain Future Upside

The analyst fair value estimate for Roche Holding has been raised from CHF 230.00 to CHF 262.39, as analysts factor in updated assumptions for revenue growth, profit margins, and a lower future P/E multiple, alongside recent Street price target increases and more constructive views on the pipeline and diagnostics pricing. Analyst Commentary Recent research has highlighted a mixed but generally more constructive tone around Roche, with fresh attention on pricing decisions, the pipeline, and relative positioning versus peers in diagnostics and genomics.
내러티브 업데이트 • Feb 21

ROG: Pipeline Milestones And Digital Execution Will Shape Balanced Risk Reward Ahead

Roche Holding's updated analyst price target has moved higher to reflect a fair value shift to CHF 358.45 from CHF 323.28. Analysts point to improved growth and margin assumptions, alongside recent upgrades and higher CHF-based targets from several banks.
내러티브 업데이트 • Feb 07

ROG: 2026 Clinical Pipeline And Execution Progress Will Drive Future Rerating

Analysts have nudged their fair value estimate for Roche Holding slightly higher to CHF 428, citing a mix of updated assumptions around revenue growth, profit margins, discount rates and future P/E multiples, along with recent upward moves in Street price targets and more constructive research coverage. Analyst Commentary Bullish analysts have become more constructive on Roche in recent months, with several research notes pointing to upgraded ratings, refreshed price targets and improving sentiment around the pipeline and execution.
분석 기사 • Feb 03

Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year

As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...
새로운 내러티브 • Feb 01

Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond

About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.
내러티브 업데이트 • Jan 23

ROG: 2026 Clinical Milestones And Execution Progress Will Drive Future Rerating

Analysts have raised their price expectations for Roche Holding, citing updated assumptions that include improved revenue growth, a slightly lower projected profit margin, and a modestly reduced future P/E multiple. These changes are supported by recent rating upgrades and positive commentary on clinical catalysts and the operational outlook.
내러티브 업데이트 • Jan 09

ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution

Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.
내러티브 업데이트 • Dec 17

ROG: Pipeline Data And Digital Execution Will Shape Balanced Risk Reward Ahead

Analysts have nudged their fair value estimate for Roche Holding higher, lifting the target by about CHF 11.50 to reflect slightly stronger long term revenue growth and margin assumptions supported by recent positive readthroughs from partners, incremental pipeline visibility, and a modest firming in Street price targets. Analyst Commentary Bullish analysts emphasize that recent partner updates and pipeline milestones are incrementally improving sentiment on Roche, supporting the view that medium term growth and margin visibility are strengthening despite a still mixed backdrop.
내러티브 업데이트 • Dec 03

ROG: Pipeline Readouts And Commercial Execution Will Shape Balanced Risk Reward Ahead

Analysts modestly raise their price target on Roche Holding, reflecting an updated fair value estimate of approximately CHF 312 from about CHF 305 as they factor in slightly stronger long term revenue growth, improving margins, and supportive readthroughs from recent pipeline and partnership developments. Analyst Commentary Recent Street commentary around Roche continues to frame the company as a strategically important player in oncology, ophthalmology, and digital enablement, while also highlighting competitive and execution risks that temper upside expectations.
내러티브 업데이트 • Nov 19

ROG: Sector Pressures And Mixed Trial Results Will Shape Performance Ahead

Roche Holding’s analyst price target has been raised by CHF 10 to CHF 255. Analysts cite moderate adjustments to fair value estimates, along with continued caution regarding recent trial outcomes and sector dynamics.
분석 기사 • Aug 20

Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

SWX:ROG 1 Year Share Price vs Fair Value Explore Roche Holding's Fair Values from the Community and select yours With a...
분석 기사 • Jun 24

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
새로운 내러티브 • Feb 04

Roche Holding will see a 4.2576% revenue growth shaking the market

### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
User avatar
새로운 내러티브 • Feb 02

Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025

Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.

이익 및 매출 성장 예측

SWX:ROG - 애널리스트 향후 추정치 및 과거 재무 데이터 (CHF Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/202867,59017,32118,67323,1009
12/31/202764,96315,60916,92521,47512
12/31/202662,77114,56515,55919,70313
12/31/202563,35612,88013,07518,852N/A
9/30/202563,42211,15513,14219,066N/A
6/30/202563,4889,42913,20919,280N/A
3/31/202562,9428,85314,14719,687N/A
12/31/202462,3958,27715,08520,094N/A
9/30/202461,4889,44813,21518,103N/A
6/30/202460,58110,61911,34416,111N/A
3/31/202460,51111,05911,39516,103N/A
12/31/202360,44111,49811,44616,095N/A
9/30/202361,48611,26311,75916,313N/A
6/30/202362,53011,02812,07116,530N/A
3/31/202364,17211,72512,66117,167N/A
12/31/202265,81412,42113,25117,803N/A
9/30/202266,71613,53915,38419,869N/A
6/30/202267,61714,65717,51621,935N/A
3/31/202266,73414,29416,97221,456N/A
12/31/202165,85013,93016,42720,976N/A
9/30/202163,97413,97515,19720,346N/A
6/30/202162,09814,01913,96719,716N/A
3/31/202161,22114,15712,92219,141N/A
12/31/202060,34314,29511,87618,566N/A
9/30/202061,36113,62613,79919,949N/A
6/30/202062,37812,95715,72221,332N/A
3/31/202063,06513,22716,60721,859N/A
12/31/201963,75113,49717,49122,385N/A
9/30/201962,73612,654N/A21,210N/A
6/30/201961,72111,810N/A20,034N/A
3/31/201960,60911,155N/A20,007N/A
12/31/201859,49710,500N/A19,979N/A
9/30/201858,61110,483N/A19,131N/A
6/30/201857,72510,465N/A18,283N/A
3/31/201856,7369,549N/A18,154N/A
12/31/201755,7468,633N/A18,024N/A
9/30/201754,9619,154N/A17,578N/A
6/30/201754,1769,675N/A17,132N/A
3/31/201753,4069,626N/A16,067N/A
12/31/201652,6369,576N/A15,001N/A
9/30/201652,1099,332N/A14,678N/A
6/30/201651,5819,087N/A14,354N/A
3/31/201650,9928,975N/A14,803N/A
12/31/201550,4038,863N/A15,251N/A
9/30/201550,3648,908N/A15,077N/A
6/30/201550,3248,953N/A14,902N/A
3/31/201550,0959,143N/A15,416N/A

애널리스트 향후 성장 전망

수입 대 저축률: ROG 의 연간 예상 수익 증가율(9.3%)이 saving rate(0.5%)보다 높습니다.

수익 vs 시장: ROG 의 연간 수익(9.3%)이 Swiss 시장(11%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: ROG 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: ROG 의 수익(연간 3.1%)이 Swiss 시장(연간 4.9%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: ROG 의 수익(연간 3.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ROG의 자본 수익률은 3년 후 34.8%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/03/16 03:05
종가2026/03/16 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Roche Holding AG는 47명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
John StaszakArgus Research Company
Gerhard SchwarzBaader Helvea Equity Research
Mark PurcellBarclays